Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Mississippi for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Mississippi only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Mississippi (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Sonia Benn (NPI 1801825781)

Field	Value
Entity Type	Individual
Organization	Sonia Benn
Address	7668 Airways Blvd
City	Southaven
State	MS
ZIP	38671
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	July 2, 2006

Payer Source	Total Paid
Medicare	$2.6M
Medicaid	$0

Key Findings

This provider is effectively single‑payer: lifetime Medicare revenue is $2.6M and there is no Medicaid billing on file, so all reported public-payer activity is concentrated in Medicare. Analysts should treat this profile as a Medicare-centric oncology practice when considering payer contracting or care‑management interventions.

NPI tenure indicates an established practice presence: the provider’s NPI was enumerated 2006-07-02 (~20 years ago), suggesting long-term operation in the market. That longevity supports interpretation of the reported volumes as sustained practice patterns rather than a short-term spike.

Revenue is highly concentrated in a few high-cost oncology drugs: the precomputed top‑3 share shows the top 3 Medicare codes account for 66.4% of total Medicare revenue. The single largest line item is J9271 with $980.4K (38.1% of Medicare revenue, 22.8K claims, ranks #283 of 1841 providers nationally at the 84th percentile), with J9144 ($472K, 18.3%, 12.4K claims, rank #139 of 615, 77th percentile) and J9299 ($259.2K, 10.1%, 10.8K claims, rank #327 of 505, 35th percentile) completing the top three — this creates material dependency on immunotherapy/monoclonal antibody infusions.

The code mix aligns with a hematology/oncology infusion practice rather than a visit‑based or hospital setting: high revenues from J9271, J9144, and J9299 point to checkpoint inhibitors and monoclonal antibody infusions, while chemotherapy administration codes (96413, 96365) and supportive care agents (J2506 pegfilgrastim, J0897 denosumab) show integrated infusion and supportive oncology services. Together these codes imply an operation centered on in‑office drug administration and infusion throughput.

Competitive standing is mixed across drugs: for pembrolizumab (J9271) the provider ranks #283 of 1841 (84th percentile) and for daratumumab (J9144) ranks #139 of 615 (77th percentile), indicating solid but not dominant national participation for those agents. Other top products show weaker relative positioning (J9299 ranks #327 of 505, 35th percentile), while use of the bevacizumab biosimilar Q5107 is relatively concentrated (rank #10 of 78, 88th percentile), suggesting selective strength in certain biologics.

Several procedure and lab codes are statistical high‑volume outliers or well above typical national use: 96413 (538 claims, $47.3K revenue) is flagged as "notably above typical national volume" and ranks #573 of 7514 (92th percentile), and 96367 (735 claims, $14.7K) ranks #167 of 4032 (96th percentile) with the same "notably above typical national volume" label. Routine labs and specimen collection codes also sit at high national percentiles (80048 rank #328 of 14725, 98th percentile; 36415 rank #1337 of 86467, 98th percentile), indicating consistent same‑day lab and infusion workflows.

Office visit/E&M revenue is a small share relative to drug and infusion income: 99214 generated $43.4K (488 claims, 1.7% of Medicare revenue) and 99215 generated $30.8K (248 claims, 1.2% of Medicare revenue), so the practice’s revenue profile is driven primarily by administered drugs and infusion services rather than face‑to‑face E/M volume. This has implications for network negotiations where per‑infusion reimbursement and buy‑and‑bill arrangements will be the dominant commercial levers.

Operational signals point to high patient throughput with many low‑paid, high‑count items: large claim counts include J1439 (30.8K claims, $30.8K revenue), J0881 (21.5K claims, $42.9K revenue), and J9271 (22.8K claims), which reflect frequent administration of small‑unit or low‑paid products alongside high‑value monoclonal antibodies. The presence of biosimilars (Q5107, Q5123) and high ranks for certain lab and infusion codes suggests an infusion suite that mixes branded biologics with biosimilar adoption and routine supportive services.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

69 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	22,800	$40	$980.4K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	12,420	$40	$472K
J9299	Injection, nivolumab, 1 mg	10,800	$20	$259.2K
J0897	Injection, denosumab, 1 mg	14,040	$20	$252.7K
Q5107	Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg	5,800	$20	$133.4K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	540	$90	$47.3K
J1454	Injection, fosnetupitant 235 mg and palonosetron 0.25 mg	130	$340	$44.4K
Q5123	Injection, rituximab-arrx, biosimilar, (riabni), 10 mg	1,190	$40	$44K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	490	$90	$43.4K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	21,460	$1	$42.9K

Showing 1–10 of 69

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 69 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Mississippi Distribution

Sonia Benn — 5 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Mississippi

Full comparison — all codes billed, vs. state median

69 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	4	10	16,700	$40	$1M
J9144	3	10	13,050	$40	$631.7K
J9299	8	10	21,120	$20	$569.7K
Q5107	1	10	5,800	$20	$131.4K
J0897	8	110	3,030	$20	$95.7K
J2506	8	10	910	$80	$91.5K
J0881	1	10	21,460	$1	$50.4K
Q5123	1	10	1,190	$40	$43.7K
J1439	13	20	42,000	$1	$41.6K
J1454	1	10	70	$350	$24.9K

Showing 1–10 of 69

Related Providers

Other providers that share a Tax Identification Number (TIN) with Sonia Benn, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
The West Clinic P.C.	TN	Specialist	$0	$16M
David Portnoy	TN	Hematology & Oncology Physician	$6.5M	$0
Kurt Tauer	TN	Medical Oncology Physician	$3.9M	$0
Gang Tian	TN	Hematology & Oncology Physician	$3.8M	$0
Jason Chandler	TN	Medical Oncology Physician	$3.8M	$0
Syed Sameer Nasir	TN	Hematology & Oncology Physician	$3.5M	$0
Ramakrishna Battini	TN	Hematology & Oncology Physician	$3.3M	$0
Eric Wiedower	TN	Hematology & Oncology Physician	$2.9M	$0
Bradley Somer	TN	Hematology & Oncology Physician	$2.8M	$0
Robert Johnson	TN	Hematology & Oncology Physician	$2.8M	$0

Nearby Providers

Other providers in the same ZIP code as Sonia Benn, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Baptist Memorial Hospital-desoto, Inc,	MS	General Acute Care Hospital	$0	$41.6M
Sidhu Pediatrics, LLC	MS	Pediatrics Physician	$0	$10.8M
Desoto Pediatric Extended Care LLC	MS	Pediatric Skilled Nursing Facility	$0	$8.2M
Spectra Laboratories Inc	MS	Clinical Medical Laboratory	$1.8M	$6.2M
Desoto Family Counseling Center PLLC	MS	Community/Behavioral Health Agency	$0	$5.6M
Simple Strokestherapy Consultants, PA	MS	Physical Therapist	$0	$5.1M
John Acosta	MS	Pediatric Dentistry	$0	$4.7M
Rcg Southaven, LLC	MS	End-Stage Renal Disease (ESRD) Treatment Clinic/Center	$0	$3.9M
Roberts & Garza Orthodontics Services PLLC	MS	Orthodontics and Dentofacial Orthopedics Dentistry	$0	$3.4M
Genesis Healthcare LLC	MS	Home Health Agency	$0	$2.9M

Sonia Benn — Billing Profile & Reimbursement Data

Sign up for Sonia Benn — Billing Profile & Reimbursement Data policy alerts

Sonia Benn — Billing Profile & Reimbursement Data

Sign up for Sonia Benn — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References